Structure-energy-based predictions and network modelling of RASopathy and cancer missense mutations

被引:59
作者
Kiel, Christina [1 ,2 ]
Serrano, Luis [1 ,2 ,3 ]
机构
[1] Ctr Genom Regulat CRG, EMBL CRG Syst Biol Res Unit, Barcelona, Spain
[2] Univ Pompeu Fabra, Barcelona, Spain
[3] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain
关键词
RASopathy; FoldX; MAPK pathway; missense mutations; enedgetics; OF-FUNCTION MUTATIONS; RAS ACTIVATOR SON; TYROSINE-PHOSPHATASE SHP-2; SIGNAL-REGULATED KINASE; HUMAN GENETIC-DISEASE; CAUSE NOONAN-SYNDROME; ONCOGENIC RAS; DEVELOPMENTAL DISORDERS; GERMLINE MUTATIONS; CRYSTAL-STRUCTURE;
D O I
10.1002/msb.20145092
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The Ras/MAPK syndromes ('RASopathies') are a class of developmental disorders caused by germline mutations in 15 genes encoding proteins of the Ras/mitogen-activated protein kinase (MAPK) pathway frequently involved in cancer. Little is known about the molecular mechanisms underlying the differences in mutations of the same protein causing either cancer or RASopathies. Here, we shed light on 956 RASopathy and cancer missense mutations by combining protein network data with mutational analyses based on 3D structures. Using the protein design algorithm FoldX, we predict that most of the missense mutations with destabilising energies are in structural regions that control the activation of proteins, and only a few are predicted to compromise protein folding. We find a trend that energy changes are higher for cancer compared to RASopathy mutations. Through network modelling, we show that partly compensatory mutations in RASopathies result in only minor downstream pathway deregulation. In summary, we suggest that quantitative rather than qualitative network differences determine the phenotypic outcome of RASopathy compared to cancer mutations.
引用
收藏
页数:14
相关论文
共 79 条
  • [1] Using protein design algorithms to understand the molecular basis of disease caused by protein-DNA interactions: the Pax6 example
    Alibes, Andreu
    Nadra, Alejandro D.
    De Masi, Federico
    Bulyk, Martha L.
    Serrano, Luis
    Stricher, Francois
    [J]. NUCLEIC ACIDS RESEARCH, 2010, 38 (21) : 7422 - 7431
  • [2] The intermediate-activity L597VBRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway
    Andreadi, Catherine
    Cheung, Lai-Kay
    Giblett, Susan
    Patel, Bipin
    Jin, Hong
    Mercer, Kathryn
    Kamata, Tamihiro
    Lee, Pearl
    Williams, Alexander
    McMahon, Martin
    Marais, Richard
    Pritchard, Catrin
    [J]. GENES & DEVELOPMENT, 2012, 26 (17) : 1945 - 1958
  • [3] The RAS/MAPK syndromes: Novel roles of the RAS pathway in human genetic disorders
    Aoki, Yoko
    Niihori, Tetsuya
    Narumi, Yoko
    Kure, Shigeo
    Matsubara, Yoichi
    [J]. HUMAN MUTATION, 2008, 29 (08) : 992 - 1006
  • [4] Gain-of-Function Mutations in RIT1 Cause Noonan Syndrome, a RAS/MAPK Pathway Syndrome
    Aoki, Yoko
    Niihori, Tetsuya
    Banjo, Toshihiro
    Okamoto, Nobuhiko
    Mizuno, Seiji
    Kurosawa, Kenji
    Ogata, Tsutomu
    Takada, Fumio
    Yano, Michihiro
    Ando, Toru
    Hoshika, Tadataka
    Barnett, Christopher
    Ohashi, Hirofumi
    Kawame, Hiroshi
    Hasegawa, Tomonobu
    Okutani, Takahiro
    Nagashima, Tatsuo
    Hasegawa, Satoshi
    Funayama, Ryo
    Nagashima, Takeshi
    Nakayama, Keiko
    Inoue, Shin-ichi
    Watanabe, Yusuke
    Ogura, Toshihiko
    Matsubara, Yoichi
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2013, 93 (01) : 173 - 180
  • [5] Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation
    Araki, Toshiyuki
    Chan, Gordon
    Newbigging, Susan
    Morikawa, Lily
    Bronson, Roderick T.
    Neel, Benjamin G.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (12) : 4736 - 4741
  • [6] Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2
    Barford, D
    Neel, BG
    [J]. STRUCTURE, 1998, 6 (03) : 249 - 254
  • [7] Stops along the RAS pathway in human genetic disease
    Bentires-Alj, M
    Kontaridis, MI
    Neel, BG
    [J]. NATURE MEDICINE, 2006, 12 (03) : 283 - 285
  • [8] Berger AH, 2014, ONCOGENE IN PRESS
  • [9] Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype
    Brems, Hilde
    Chmara, Magdalena
    Sahbatou, Mourad
    Denayer, Ellen
    Taniguchi, Koji
    Kato, Reiko
    Somers, Riet
    Messiaen, Ludwine
    De Schepper, Sofie
    Fryns, Jean-Pierre
    Cools, Jan
    Marynen, Peter
    Thomas, Gilles
    Yoshimura, Akihiko
    Legius, Eric
    [J]. NATURE GENETICS, 2007, 39 (09) : 1120 - 1126
  • [10] Transformation efficiency of RasQ61 mutants linked to structural features of the switch regions in the presence of Raf
    Buhrman, Greg
    Wink, Glenna
    Mattos, Carla
    [J]. STRUCTURE, 2007, 15 (12) : 1618 - 1629